Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maveropepimut-S + pembrolizumab
- Development stage
- Unknown
- Lead developer
- BioVaxys Technology Corporation
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Maveropepimut-S + pembrolizumab is an investigational combination therapy comprising the cancer vaccine maveropepimut-S (MVP-S, formerly DPX-Survivac) and the immune checkpoint inhibitor pembrolizumab (Keytruda). Maveropepimut-S is a peptide-based T-cell activating immunotherapy delivered by a lipid-based platform targeting survivin, a tumor-associated antigen overexpressed in multiple cancers. Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1) that relieves immune suppression and enhances antitumor T-cell activity. The combination is designed to synergistically stimulate immune responses against survivin-expressing tumors, supported by clinical data in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and platinum-resistant/recurrent epithelial ovarian cancer (EOC). In these indications, the regimen is often administered with intermittent low-dose cyclophosphamide as an immune adjuvant, but core clinical evaluation is for the doublet.
- Brand names
- Keytruda
- Other names
- MVP-S + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on maveropepimut-S + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maveropepimut-S + pembrolizumab.